Publication
Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerB Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Likecivic_curation1.00
- drugDasatinibcivic_curation1.00
- drugImatinibcivic_curation1.00
- geneABL1civic_curation1.00
- geneCSF1Rcivic_curation1.00
- variantABL1 Fusioncivic_curation1.00
- variantABL1 Fusioncivic_curation1.00
- variantCSF1R Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 31434701
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ABL2 Fusion1 | ||||||||
| Imatinib | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 1 | submitted | EID12513A 27-year-old male (Patient #17, Table 1) with B-ALL harbored a ZC3HAV1(exon 12)::ABL2(exon 2) fusion, concurrent CD200-BTLA and IKZF1 (exons 2–7) deletions, and a gain of chromosome X, presenting wit… (full text at CIViC) PMID 31434701 · Tanasi et al., 2019 · Open in CIViC | civic |
| ABL1 Fusion1 | ||||||||
| (prognostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Prognostic | C | Supports Poor Outcome | 2 | accepted | EID9153This retrospective study reported the outcome of 24 patients with Ph-like acute lymphoblastic leukemia (Ph-like ALL) harboring ABL-class fusions who were treated with a combination of tyrosine kinase … (full text at CIViC) PMID 31434701 · Tanasi et al., 2019 · Open in CIViC | civic |
| CSF1R Fusion1 | ||||||||
| Imatinib | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID9360This study describes a cohort of 24 patients with BCR-ABL1-like B-ALL and ABL-class kinase rearrangement exposed to TKI frontline or at relapse, who showed favorable MRD response and outcome. Specific… (full text at CIViC) PMID 31434701 · Tanasi et al., 2019 · Open in CIViC | civic |
| ABL1 Fusion1 | ||||||||
| Dasatinib + ImatinibCombination | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID13330In a cohort of six patients with NUP214::ABL1-positive Ph-like B-ALL, detected by multiplex molecular assays for fusion transcript identification, including RNA sequencing, treatment with ABL-directed… (full text at CIViC) PMID 31434701 · Tanasi et al., 2019 · Open in CIViC | civic |
| ABL1 Fusion1 | ||||||||
| Dasatinib | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID9211This retrospective study reported the outcome of 24 patients with Ph-like acute lymphoblastic leukemia (Ph-like ALL) harboring ABL-class fusions, who were treated with a combination of tyrosine kinase… (full text at CIViC) PMID 31434701 · Tanasi et al., 2019 · Open in CIViC | civic |